With several efforts to resurrect American drug manufacturing already underway, congressional members on both sides of the aisle are setting their sights on one of the nation’s chief economic rivals.
The Senate has signed off on innovation and competition legislation designed to boost American competitiveness, restore the country’s manufacturing base and curb its reliance on China for critical supplies—especially drugs and medical devices, reports FiercePharma.
Supply chain complications
The bill comes as war in Ukraine further complicates a supply chain already famously strained by the COVID-19 pandemic and follows other, more tangible efforts to beef up U.S. manufacturing of drugs and medical equipment.
Specifically, the Senate on Monday voted to substitute the text of the America COMPETES Act, which passed muster in the House earlier this year, with that of the Senate’s U.S. Innovation and Competition Act of 2021. The Senate then voted 68-28 to approve the amended bill, shooting it back to the House.
The move sets the stage for a conference where Senate and House negotiators will attempt to agree on a final bill, the U.S. Senate Committee on Commerce, Science and Transportation said in a release.
Did you subscribe to our daily Newsletter?
It’s Free! Click here to Subscribe
Source: FiercePharma
